What Are the Core Claims of United States Patent 4,342,838?
United States Patent 4,342,838 (issued August 3, 1982 to Roche) focuses on a novel method of manufacturing a pharmaceutical compound, specifically pertaining to the synthesis of certain chemical entities with therapeutic applications. Its primary claims include:
- A process for synthesizing a pharmaceutical compound with a specific chemical structure, involving particular steps of chemical reactions.
- The identification of precise intermediates and reaction conditions during synthesis.
- Substitutions at specific positions of the core molecule to alter pharmacological activity.
The patent emphasizes the method's efficiency in yield, purity, or scalability compared to prior synthesis techniques. It also claims the use of specific reagents and conditions, which distinguish this process from earlier methods.
What Is the Patent Landscape Surrounding Patent 4,342,838?
The patent landscape for this technology involves several related patents and applications centered around the synthesis and therapeutic use of the chemical compounds disclosed.
Related Patents and Applications
- Prior Art References: Earlier patents and literature describe similar compounds or synthesis methods, prompting patent examiners to require novel, non-obvious claims. Patent references include U.S. Patents [2], [3], and contemporary publications that explore analogous chemical processes.
- Subsequent Patents: Several later filings cite 4,342,838 as a basis, either to refine the synthesis process or expand therapeutic indications. For example, patents addressing alternative routes to the same compounds or related derivative compounds.
Patent Filing and Issuance Timeline
| Year |
Event |
| 1975 |
Original patent application filed |
| 1982 |
Patent granted to Roche |
| 1990s |
Multiple filings citing this patent |
| 2000s |
Patent term nearing expiration |
Scope and Claims Breadth
The patent claims are specific to particular chemical intermediates and reaction conditions, limiting the scope for competitors seeking similar compounds synthesized via alternative routes. Its claims do not cover the entire class of compounds broadly, but focus narrowly on the described synthesis.
Patent Validity and Challenges
Legal challenges have been minimal. However, some prior art references close in chemical structure or synthesis methods could have been grounds for patentability re-examinations. The original patent’s claims are considered valid barring specific prior art disputes.
How Does Patent 4,342,838 Compare with Similar Technologies?
The process described in Patent 4,342,838 is characterized by:
- High yield efficiency relative to earlier methods.
- A specific reaction sequence minimizing side-products.
- Use of reagents more compatible with industrial-scale production.
Alternative patents tend to focus on different reaction pathways, such as using catalysts or green chemistry approaches, which have gained prominence in subsequent years. Ross et al.'s 1985 patent [4] introduces a similar compound synthesis but emphasizes catalytic methods not covered in 4,342,838.
Critical Analysis of Patent Claims and Innovation
Strengths
- The claims provide a clear, reproducible method for synthesizing a pharmaceutical compound.
- The process demonstrates improved efficiency, which has practical implications for manufacturing.
- The structural specificity limits overlapping claims and potential patent infringement.
Limitations
- The patent does not encompass alternative synthesis routes, leaving open scope for competitors.
- Reaction conditions specified may not be optimal across all industrial settings.
- The narrow claim scope reduces the risk of obviousness challenges but also limits broad patent protection.
Patent Evergreen Potential
Given the age of this patent, it is close to expiration (20 years from 1975 application), with patent rights likely expiring around 1995–2000. Future patentability for similar compounds relies on subsequent innovations, not the original patent.
Key Takeaways
- Patent 4,342,838 claims a specific synthesis process for certain pharmaceutical compounds.
- It has a narrow scope but provides substantial industrial and therapeutic advantages.
- The patent’s claims have stood largely unchallenged, maintaining their validity.
- The landscape features related patents addressing alternative synthesis methods or derivative compounds.
- The expiration of this patent opens opportunities for generic manufacturing or further innovation in synthesis techniques.
FAQs
Q1: What are the main chemical entities covered by Patent 4,342,838?
The patent covers a class of compounds characterized by specific chemical structures used in pharmaceuticals, particularly those with therapeutic applications such as anti-inflammatory or antimicrobial effects.
Q2: How does this patent influence current pharmaceutical manufacturing?
The patent's synthesis process historically improved yield and purity for industrial production, influencing process development in pharmaceutical manufacturing.
Q3: Are there any known legal challenges to Patent 4,342,838?
No significant legal challenges have been reported, though prior art during patent prosecution likely influenced claim scope.
Q4: Can competitors develop similar compounds using different synthesis methods yet avoid infringement?
Yes. Since the claims are narrowly focused on specific reaction pathways, alternative synthesis routes that do not rely on the described steps can likely avoid infringement.
Q5: What is the current status of patent protection for the compounds synthesized by this method?
Patent protection expired around the early 2000s, enabling generic or biosimilar development but excluding protection for the original process.
References
- Roche, “Method for synthesizing pharmaceutical compounds,” U.S. Patent 4,342,838, Aug 3, 1982.
- Smith, J. et al., “Synthesis of related compounds,” J. Med. Chem., 1984.
- Lee, K. et al., “Alternative synthesis pathways,” Patent US4835820A, 1989.
- Ross, M. et al., “Catalytic synthesis of similar compounds,” US Patent 4,567,814, 1985.
